Brokerages set target price for Karuna Therapeutics, Inc. (NASDAQ:KRTX) at $173.18



Karuna Therapeutics, Inc. (NASDAQ: KRTX – Get Rating) has received a consensus “Buy” recommendation from the twelve brokerages that currently cover the company, MarketBeat.com reports. One equity research analyst gave the stock a hold rating and eleven gave the company a buy rating. The 1-year average target price among brokers who have hedged the stock over the past year is $173.18.

KRTX has been the subject of several research analyst reports. Mizuho lowered his price target on Karuna Therapeutics shares from $182.00 to $178.00 and set a “buy” rating for the company in a Thursday, March 3 research report. Jefferies Financial Group raised its price target on Karuna Therapeutics shares from $180.00 to $183.00 and gave the stock a “buy” rating in a Tuesday, March 8 research report. Berenberg Bank assumed coverage for Karuna Therapeutics shares in a Thursday, March 31 research report. They set a “buy” rating and a price target of $190.00 for the company. Zacks Investment Research upgraded shares of Karuna Therapeutics from a “sell” rating to a “hold” rating in a Tuesday, March 8 research report. Finally, Wedbush raised its price target on Karuna Therapeutics shares from $167.00 to $176.00 and gave the company an “outperform” rating in a Monday, Jan. 24 research report.

In related news, director Atul Pande sold 2,500 shares in a trade that took place on Tuesday, February 1. The shares were sold at an average price of $110.80, for a total transaction of $277,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link. Additionally, insider Stephen K. Brannan sold 7,728 shares in a trade that took place on Tuesday, February 1. The shares were sold at an average price of $110.05, for a total transaction of $850,466.40. The disclosure of this sale can be found here. In the past ninety days, insiders have sold 28,184 shares of the company valued at $3,226,671. Insiders of the company own 18.10% of the shares of the company.

A number of hedge funds have recently increased or reduced their holdings in the stock. ARCH Venture Management LLC acquired a new equity stake in Karuna Therapeutics during the fourth quarter valued at approximately $381,586,000. BlackRock Inc. increased its holdings of Karuna Therapeutics shares by 3.5% during the fourth quarter. BlackRock Inc. now owns 1,638,617 shares of the company valued at $214,659,000 after acquiring an additional 55,120 shares during the period. Wellington Management Group LLP increased its equity stake in Karuna Therapeutics by 5.8% during the third quarter. Wellington Management Group LLP now owns 1,001,886 shares of the company valued at $122,560,000 after acquiring an additional 55,305 shares during the period. Viking Global Investors LP increased its holdings of Karuna Therapeutics shares by 5.6% during the third quarter. Viking Global Investors LP now owns 868,696 shares of the company valued at $106,268,000 after acquiring an additional 46,231 shares during the period. Finally, Farallon Capital Management LLC increased its equity stake in Karuna Therapeutics by 11.1% during the third quarter. Farallon Capital Management LLC now owns 700,000 shares of the company valued at $85,631,000 after acquiring an additional 70,000 shares during the period. 93.21% of the shares are held by institutional investors and hedge funds.

Shares of KRTX traded at $5.63 at midday on Friday, hitting $137.70. The company had a trading volume of 156,517 shares, compared to an average volume of 200,240. The company has a fifty-day simple moving average of $116.18 and a 200-day simple moving average of $121.75 . Karuna Therapeutics has a fifty-two week low of $93.77 and a fifty-two week high of $161.98.

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) last reported quarterly results on Thursday, February 24. The company reported ($0.94) earnings per share for the quarter, beating the Zacks consensus estimate of ($1.52) by $0.58. The company posted revenue of $36.96 million in the quarter, versus analyst estimates of $5.38 million. In the same quarter last year, the company achieved EPS of ($0.89). As a group, equity research analysts expect Karuna Therapeutics to post earnings per share of -7.6 for the current year.

Karuna Therapeutics Company Profile (Get an evaluation)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological disorders. Its lead product candidate is KarXT, an oral muscarinic receptor modulator that is in a Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.

See also

Analyst Recommendations for Karuna Therapeutics (NASDAQ: KRTX)



Get news and reviews for Karuna Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Karuna Therapeutics and related companies with MarketBeat.com’s FREE daily newsletter.

Previous Who is rowing your boat?
Next Sunrun Inc. (NASDAQ:RUN) receives an average price target of $62.87 from analysts